Marie-Pierre Dehouck

Prof. Marie-Pierre Dehouck

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SLStefan Lundquist
Stefan Lundquist
MRMila Renftel
Mila Renftel
JBJulien Brillault
Julien Brillault
LTLaurence Tilloy-Fenart
Laurence Tilloy-Fenart
RCRoméo Cecchelli
Roméo Cecchelli
MDMarie-Pierre Dehouck
Marie-Pierre Dehouck

Verified
Journal Article
Open access
PDF file
ADAurore Drolez
Aurore Drolez
EVElodie Vandenhaute
Elodie Vandenhaute
Philippe DelannoyPhilippe Delannoy
Philippe Delannoy
JDJustine Hélène Dewald
Justine Hélène Dewald
FGFabien Gosselet
Fabien Gosselet
CMCaroline Mysiorek
Caroline Mysiorek
The ST6GALNAC5 gene that encodes an α2,6-sialyltransferase involved in the biosynthesis of α-series gangliosides, was previously identified as one of the genes that mediate breast cancer metastasis to the brain. We have shown that the expression of ST6GALNAC5 in MDA-MB-231 breast cancer cells resulted in the expression of GD1α ganglioside at the cell surface. By using a human blood-brain barrier in vitro model recently developed, consisting in CD34+ derived endothelial cells co-cultivated with pericytes, we show that ST6GALNAC5 expression decreased the interactions between the breast cancer cells and the human blood-brain barrier.

1 January 2012 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
EVElodie Vandenhaute
Elodie Vandenhaute
MCMaxime CULOT
Maxime CULOT
FGFabien Gosselet
Fabien Gosselet
LDLucie Dehouck
Lucie Dehouck
CGCatherine Godfraind
Catherine Godfraind
MRMarie-Magdeleine Ruchoux
Marie-Magdeleine Ruchoux
The function of pericytes remains questionable but with improved cultured technique and the use of genetically modified animals, it has become increasingly clear that pericytes are an integral part of blood–brain barrier (BBB) function, and the involvement of pericyte dysfunction in certain cerebrovascular diseases is now emerging. The porcine stress syndrome (PSS) is the only confirmed, homologous model of malignant hyperthermia (MH) in veterinary medicine. Affected animals can experience upon slaughter a range of symptoms, including skeletal muscle rigidity, metabolic acidosis, tachycardia and fever, similar to the human syndrome. Symptoms are due to an enhanced calcium release from intracellular stores. These conditions are associated with a point mutation in ryr1/hal gene, encoding the ryanodine receptor, a calcium channel. Important blood vessel wall muscle modifications have been described in PSS, but potential brain vessel changes have never been documented in this syndrome.

8 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
MDMarie-Pierre Dehouck
Marie-Pierre Dehouck
MTMasanori Tachikawa
Masanori Tachikawa
YHYutaro Hoshi
Yutaro Hoshi
KOKotaro Omori
Kotaro Omori
CMClaude-Alain Maurage
Claude-Alain Maurage
Yannis KaramanosYannis Karamanos
Yannis Karamanos
We previously developed an in vitro model of the human blood–brain barrier (BBB) based on the use of endothelial cells derived from CD34+-hematopoietic stem cells and cultured with brain pericytes. The purpose of the present study was to provide information on the protein expression levels of the transporters, receptors, tight junction/adherence junction molecules, and transporter-associated molecules of human brain-like endothelial cells (hBLECs). The absolute protein expression levels were determined by liquid chromatography–mass spectrometry-based quantitative targeted absolute proteomics and compared with those from human brain microvessels (hBMVs). The protein levels of CD144, CD147, MRP4, Annexin A6 and caveolin-1 showed more than 3-fold abundance in hBLECs, those of MCT1, Connexin 43, TfR1, and claudin-5 showed less than 3-fold differences, and the protein levels of other drug efflux transporters and nutrient transporters were less represented in hBLECs than in hBMVs. It is noteworthy that BCRP was more expressed than MDR1 in hBLECs, as this was the case for hBMVs. These results suggest that transports mediated by MCT1, TfR1, and claudin-5-related tight junction function reflect the in vivo BBB situation. The present study provided a better characterization of hBLECs and clarified the equivalence of the transport characteristics between in vitro BBB models and in vivo BBB models using LC-MS/MS-based protein quantification.

16 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EMElisa Moya
Elisa Moya
EVElodie Vandenhaute
Elodie Vandenhaute
EREleonora Rizzi
Eleonora Rizzi
MBMarie-Christine Boucau
Marie-Christine Boucau
JHJohan Hachani
Johan Hachani
MDMarie-Pierre Dehouck
Marie-Pierre Dehouck
Central nervous system (CNS) diseases are one of the top causes of death worldwide. As there is a difficulty of drug penetration into the brain due to the blood–brain barrier (BBB), many CNS drugs treatments fail in clinical trials. Hence, there is a need to develop effective CNS drugs following strategies for delivery to the brain by better selecting them as early as possible during the drug discovery process. The use of in vitro BBB models has proved useful to evaluate the impact of drugs/compounds toxicity, BBB permeation rates and molecular transport mechanisms within the brain cells in academic research and early-stage drug discovery. However, these studies that require biological material (animal brain or human cells) are time-consuming and involve costly amounts of materials and plastic wastes due to the format of the models. Hence, to adapt to the high yields needed in early-stage drug discoveries for compound screenings, a patented well-established human in vitro BBB model was miniaturized and automated into a 96-well format. This replicate met all the BBB model reliability criteria to get predictive results, allowing a significant reduction in biological materials, waste and a higher screening capacity for being extensively used during early-stage drug discovery studies.

4 June 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
ACAndré-Guilhem Calas
André-Guilhem Calas
AHAnne-Sophie Hanak
Anne-Sophie Hanak
NJNina Jaffré
Nina Jaffré
ANAurélie Nervo
Aurélie Nervo
JDJosé Dias
José Dias
FNFlorian Nachon
Florian Nachon
(1) Background: Human exposure to organophosphorus compounds employed as pesticides or as chemical warfare agents induces deleterious effects due to cholinesterase inhibition. One therapeutic approach is the reactivation of inhibited acetylcholinesterase by oximes. While currently available oximes are unable to reach the central nervous system to reactivate cholinesterases or to display a wide spectrum of action against the variety of organophosphorus compounds, we aim to identify new reactivators without such drawbacks. (2) Methods: This study gathers an exhaustive work to assess in vitro and in vivo efficacy, and toxicity of a hybrid tetrahydroacridine pyridinaldoxime reactivator, KM297, compared to pralidoxime. (3) Results: Blood–brain barrier crossing assay carried out on a human in vitro model established that KM297 has an endothelial permeability coefficient twice that of pralidoxime. It also presents higher cytotoxicity, particularly on bone marrow-derived cells. Its strong cholinesterase inhibition potency seems to be correlated to its low protective efficacy in mice exposed to paraoxon. Ventilatory monitoring of KM297-treated mice by double-chamber plethysmography shows toxic effects at the selected therapeutic dose. This breathing assessment could help define the No Observed Adverse Effect Level (NOAEL) dose of new oximes which would have a maximum therapeutic effect without any toxic side effects.